



PORTAL HYPERTENSION

DR. MOHIT A. CHAUDHARY

RESIDENT MD (MEDICINE)

PRAVARA RURAL HOSPITAL, LONI


DEFINITION

- *Portal hypertension* is defined as the elevation of the hepatic venous pressure gradient to > 5 mmhg.
- Clinically significant portal hypertension is present when gradient exceeds 10 mmHg.
- Risk of variceal bleeding increases beyond a gradient of 12 mmHg.

MEASUREMENT OF PORTAL PRESSURE

- Hepatic venous pressure gradient (HVPG) is the difference between wedged hepatic venous pressure (WHVP) and free hepatic venous pressure (FHVP).
- Measurements are taken in the WHVP and FHVP positions by inflating and deflating the balloon in the tip of the catheter, introduced through internal jugular or femoral vein

ANATOMY OF PORTAL VENOUS SYSTEM



ANATOMY OF PORTAL VENOUS SYSTEM

- Portal vein is formed by the union of the superior mesenteric vein and the splenic vein just posterior to the head of the pancreas at the level of second lumbar vertebra
- Portal blood flow in man is about 1000 to 1200 ml/min



CLASSIFICATION AND CAUSES

- Prehepatic
 - Portal vein thrombosis
 - Splenic vein thrombosis
 - Massive splenomegaly

CLASSIFICATION AND CAUSES

- Hepatic

1. Presinusoidal:

- schistosomiasis

- Congenital hepatic fibrosis

2. Sinusoidal:

- Cirrhosis of liver

- alcoholic hepatitis

3. Postsinusoidal:



CLASSIFICATION AND CAUSES

- Posthepatic

- Budd-Chiari Syndrome

- Inferior vena cava obstruction

- cardiac causes:

- Restrictive cardiomyopathy

- Constrictive pericarditis

- Severe congestive cardiac failure

PATHOPHYSIOLOGY

- The fundamental haemodynamic abnormality is an increased resistance to portal blood flow.
- Increased portal vascular resistance leads to gradual reduction in the flow of portal blood to the liver and simultaneously to the development of collateral vessels, allowing portal blood to bypass the liver and enter the systemic circulation directly.
- Collaterals develop when the pressure gradient between the portal and hepatic vein rises above a certain threshold, a process involves angiogenic factors.
- At the same time portal flow increases in the splanchnic bed due to splanchnic vasodilatation and increased cardiac output


PATHOPHYSIOLOGY

- Portal vascular resistance is increased in chronic liver disease.



PATHOPHYSIOLOGY IN CIRRHOSIS

- Portal venous blood is diverted into collateral channels and some bypass the liver cells and is shunted directly into the hepatic venous radicles in fibrous septa.
- These portohepatic anastomosis develop from pre-existing sinusoids enclosed in the septa



- The regenerating nodules become divorced from their portal blood supply and are nourished by the hepatic artery.
- The obstruction to portal flow is partially due to nodules which compress hepatic venous

Cirrhosis

Resistance portal flow

MECHANICAL

Fibrosis

Nodules

Disse collagen

DYNAMIC

Myofibroblasts

Endothelial cells

Portal collaterals

Rise in portal pressure

Development portal systemic collaterals



COLLATERAL CIRCULATION

- Normally 100 % of the portal venous blood flow can be recovered from the hepatic veins, whereas in cirrhosis only 13 % is obtained.
- The remainder enters collateral channels which form four main groups

COLLATERAL CIRCULATION

- Group 1 (At the cardia of stomach and at the anus)

At the cardia of stomach


Portal System {
Left gastric vein
Posterior gastric vein
Short gastric veins

ANASTOMOSE

WITH



Caval system {
Intercostal veins
Diaphragmo-esophageal vein
Azygous minor veins



COLLATERAL CIRCULATION

- Group I:

At the anus

Portal system

Superior haemorrhoidal vein

Anastomose


with



Caval system

Middle haemorrhoidal vein

Inferior Haemorrhoidal vein




COLLATERAL CIRCULATION

- Group II:

At the umbilicus,

In the falciform ligament through the paraumbilical veins anastomosing with superficial abdominal veins




COLLATERAL CIRCULATION

- Group III:

Where the abdominal organs are in contact with retroperitoneal tissues or adherent to abdominal wall.

These collaterals run from liver to diaphragm and in spleenorenal ligament and omentum.



ASCITES IN PORTAL HYPERTENSION

- ★ Factors involved in the pathogenesis of ascites
 - Increased portal pressure with vasodilation of splanchnic arterial system.
 - Sodium retention due to activation of the raas due to hyperaldosteronism, causing fluid accumulation and expansion of ecf
 - Sodium retention is also the consequence of a homeostatic response caused by underfilling of arterial circulation secondary to splanchnic vasodilatation.
 - Increased production of splanchnic lymph.

CLINICAL FEATURES

- History:

Cirrhosis is the commonest cause.

Past abdominal infectious conditions, is important in extrahepatic portal vein thrombosis.

Inherited or acquired thrombotic conditions drugs like sex hormones predispose to portal and hepatic vein thrombosis.

Haematemesis is the commonest presentation.

Melaena without haematemesis may result from bleeding varices


CLINICAL FEATURES

- Abdominal wall veins:

Prominent collateral veins radiating from umbilicus are termed caput medusae.

A venous hum may be heard usually in the region of xiphoid process or umbilicus.

- Splenomegaly (Mild to moderate)
- Ascites
- Anorectal varices
- Feter hepaticus



DIAGNOSIS OF PORTAL HYPERTENSION

- Imaging :

- Ultrasonography

- Doppler Ultrasonography

- CT Contrast arteriopography

- MR angiography




COMPLICATIONS

- Variceal bleeding
- Congestive gastropathy
- Hypersplenism
- Ascites
- Iron deficiency anaemia
- Renal failure
- Hepatic encephalopathy

DIAGNOSIS OF VARICES

- Endoscopy is the best screening test to detect varices.



DIAGNOSIS OF VARICES

- Endoscopy is the best screening test to detect varices.



MANAGEMENT OF ACUTE VARICEAL BLEED

- Diagnostic endoscopy is performed first.
- Haemodynamic monitoring is done.
- Fresh frozen plasma, vitamin K & platelet transfusion if necessary given to prevent further worsening of coagulation.
- Hepatic encephalopathy is prevented by giving lactulose.


- Therapeutic options available are:

Vasoactive drugs

Endoscopic sclerotherapy

Variceal banding


Sengstaken-Blakemore tube



MANAGEMENT OF ACUTE VARICEAL BLEED


- Vasoactive drugs

1. Vasopressin & Telipressin. Both lower portal venous pressure by constriction of splanchnic arterioles.
2. Spmatostatin: in addition to constriction of splanchnic arterioles, it inhibits splanchnic vasodilatory peptides like glucagon.
3. Octreotide.



MANAGEMENT OF ACUTE VARICEAL BLEED

- The combination of immediate use of a vasoactive drug and endoscopic banding ligation or sclerotherapy is the therapeutic gold standard for acute treatment of bleeding varices




MANAGEMENT OF ACUTE VARICEAL BLEED

- TIPS:


An expandable metal stent is inserted between portal vein and hepatic vein producing an intrahepatic portosystemic shunt

Approach is taken through internal jugular vein



MANAGEMENT OF ACUTE VARICEAL BLEED


- Use of Senstaken-Blakemore tube has decreased now a days, with use of vasoactive drugs, sclerotherapy and TIPS.



MANAGEMENT OF RECURRENT VARICEAL BLEED

Group designation	A	B	C
Serum bilirubin* (mg/dL)	Below 2.0	2.0-3.0	Over 3.0
Serum albumin (g/dL)	Over 3.5	3.0-3.5	Under 3.0
Ascites	None	Easily controlled	Poorly controlled
Neurological disorder	None	Minimal	Advanced coma
Nutrition	Excellent	Good	Poor: 'wasting'

MANAGEMENT OF RECURRENT VARICEAL HEMORRHAGE



SECONDARY PREVENTION OF VARICEAL BLEEDING

- Beta-blockers are used as secondary measure to prevent recurrent variceal bleeding.
- Propranolol or nadolol is effective in reducing portal venous pressure.
- Administration of these drugs at doses that reduce the heart rate by 25 % has been shown to be effective in the primary prevention of variceal bleeding.



THANK YOU